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Pharmacotherapy in psychiatry is characterised by a clinical 
response of patients frequently delayed by several days or even weeks. 
Moreover, there are no firm biological parameters which can be 
monitored to get an objective picture of the clinical outcome in patients 
suffering from schizophrenia or an affective disorder, except for some 
adverse effects. Therapeutic drug effects are often subtle, changes in 
psychopathology have to be measured using adequate rating scales. 
Such scales are also used for the qualitative and quantitative analysis 
of adverse effects such as sedation, inner tension, anxiety, suicidal 
ideas, extrapyramidal symptoms. On the other hand, laboratory 
exams have to be included to monitor possible adverse effects at e.g. 
the haematological level [1,2]. Besides, patients often lack adherence 
to the treatment. This situation but also environmental, personal and 
genetic factors are responsible for a high interindividual variability of 
the metabolism and pharmacokinetics in the subjects. This variability 
has consequences on the pharmacodynamics of the therapeutic agents. 
Therefore, therapeutic drug monitoring and pharmacogenetics tests 
have been introduced as valid instruments to optimise treatment [3].
Most psychotropic drugs such as antidepressants and 
antipsychotics are metabolised by genetically polymorphic forms of 
cytochrome P-450 (CYP) and some of them are also substrates and/or 
inhibitors/inducers of the transporter protein ABCB1 (P-glycoprotein 
(PgP). Recently, several groups of authors have raised the question 
whether time has come for implementation of pharmacogenomics in 
psychiatry in order to promote personalized therapy [4]. While the 
general strategy of TDM includes consideration of the role of CYP in 
drug-drug interactions and in the pharmacogenetic factors responsible 
for the variability of drug plasma concentrations, this seems to be far 
less the case with PgP [3].
PgP belongs to the family of the ATP-binding cassette (ABC) 
transporters and acts as an efflux transporter in that it limits the access 
of drugs and other xenobiotics to the organism at different levels, e.g. 
in the intestine, kidney and liver, but also at the blood-brain barrier 
[5]. This protein is characterised by multiple membrane-spanning 
domains that determine a pore and it contains intracellular nucleotide-
binding domains for ATP-dependent translocation of substrates across 
the cell membrane [6]. Psychotropic drugs such as e.g. citalopram but 
not mirtazapine is PgP substrates. PgP is encoded by the polymorphic 
ABCB1 gene. Thousands of SNPs have been described, including 
several hundred in the coding region. This gave rise to the hypothesis 
that genetic variants of PgP differ in their ability to influence the 
transport of drugs and substrates. In one of the first studies, the authors 
observed that in depressive patients treated with PgP substrates (incl. 
amitriptyline, citalopram, venlafaxine and others), there was an 
association between several SNPs of ABCB1 and their clinical outcome 
[7]. However, there are conflicting results about the effect of the genetic 
variability of ABCB1 on the clinical outcome of patients treated with 
antidepressants. Some authors [8] therefore recommend ABCB1 
genotyping, but others conclude that there is insufficient evidence to 
propose ABCB1 genotyping in clinical routine conditions [9-11]. 
Therefore, it is valuable that there exist independent organisations, 
such as the Clinical Pharmacogenetics Implementation Consortium 
(CIPC) (https://cpicpgx.org) and the Pharmacogenomics 
Knowledgebase (PharmGKB) (https://www.pharmgkb.org/) hosted by 
the University of Stanford who analyse the literature in this field [12-
14]. They publish recommendations for the selection of therapeutic 
drugs and dose adaptations based on the results of pharmacogenetics 
tests, on information about the relationship between genes and gene 
variants, and the clinical efficacy and tolerance on the result of the 
pharmacological treatment. The recommendations are developed 
for individual drug – gene pairs. Therefore, PharmGKB has defined 
several levels of evidence (Levels 1A – 4) for these relationships 
(https://www.pharmgkb.org/page/clinAnnLevels). Depending on 
the evidence for a particular drug – gene pair, a clinical annotation is 
then produced, and they vary between: “Testing required”, “Testing 
recommended”, “Testing actionable”, “Testing informative” (lowest 
recommendation) (https://www.pharmgkb.org/view/drug-labels.
do). It is then remarkable that despite drug – gene pairs such as 
amitriptyline – CYP2D6 (Level 1A) and citalopram - CYP2C19 (1A) 
reach highest levels, this confers them a clinical annotation by the 
FDA of (only) “Test actionable”. On the other hand, drug - gene pairs 
of antidepressants such as amitriptyline, citalopram, reach only an 
evidence level 3 for ABCB1, and they do not have any FDA annotation. 
It has to be mentioned that among neuropsychiatric drugs, there is 
almost only the drug - gene pair carbamazepine – HLA-B*15:02 and 
HLA-A*31:01 (in the domain of pharmacodynamics) which reaches 
the highest annotation, namely “Testing required”. In summary, this 
situation does not yield convincing arguments for ABCB1 genotyping 
in the everyday clinical practice, in contrast to CYP genotyping for 
well-defined drug – gene pairs.
The question then arises whether present knowledge allows 
interpretation of the role of PgP in pharmacokinetic drug – drug 
interactions. This has been examined very recently in a comprehensive 
review paper [15]. e.g., drugs which are either inhibitors and/or 
inducers of PgP could influence the transport of other drugs, substrates 
of PgP, in the human brain at the blood-brain-barrier. The authors 
found very few CNS drugs which modulate clearly PgP activity and 
which interact with other drugs at a level of clinical relevance. This 
applies only for the PgP inducers carbamazepine and phenytoin, 
and for the PgP inhibitors fluvoxamine and paroxetine. Others may 
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modulate PgP as inhibitors or inducers, but the clinical relevance 
(in vivo) is uncertain. Their list of compounds which do not have or 
demonstrate uncertain interaction with PgP is also of high interest. It 
includes drugs such as amitriptyline and citalopram. While vortioxetine 
and sertraline are recognized to modulate PgP activity in vitro, in vivo 
studies suggest that it has no clinical relevance. The examples shown 
above also illustrate the fact that many drugs do not only interact with 
Pgp, but that this activity frequently overlaps with their effect on CYP. 
Carbamazepine is also an inducer of CYP3A4, fluvoxamine is a potent 
inhibitor of CYP2C19, CYP1A2 and other CYP forms. The authors 
conclude that interpretation of drug – drug interactions in this context 
may be complex [15]. A phenotyping probe would represent a precious 
instrument to determine the degree of interaction of a comedicated 
drug on PgP activity, but one of the most cited phenotyping probe, 
digoxin, does not appear to be convenient as it does not fulfil three 
essential criteria: specificity, sensitivity and feasibility [16]. On the 
other hand, despite digoxin is also an OATP2 substrate, its use as a test 
probe for PgP can yield interesting results, in that e.g. sertraline causes 
little, clinically irrelevant increases of digoxin plasma concentrations 
in comparison to those measured in the absence of the antidepressant 
drug [17]. Unfortunately, no other psychotropic drugs were tested in 
these conditions. Therefore, further studies are needed to examine the 
role of PgP in the pharmacokinetics of psychotropic drugs, especially 
with regard to its pharmacogenomics and its role in drug-drug 
interactions. As a consequence, physicians should be aware about the 
role of PgP in potential drug-drug interactions, but other factors have 
therefore also to be considered.
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